^
    Back
    Association details:
    Biomarker:Chr amplification(1)(q21)
    Cancer:Multiple Myeloma
    Drug:filanesib (ARRY-520) (KIF11 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Med
    Title:

    Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma

    Published date:
    12/17/2021
    Excerpt:
    The combination of filanesib, bortezomib, and dexamethasone continues to show safety and encouraging activity in relapsed/refractory multiple myeloma, particularly in those patients with 1q21 gain and t(11;14).
    Secondary therapy:
    bortezomib + dexamethasone
    DOI:
    10.1002/cam4.4451